Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

Although endocrine therapy is successfully used to treat patients with estrogen receptor (ER) positive breast cancer, a substantial proportion of this population will relapse. Several mechanisms of acquired resistance have been described including activation of the mTOR pathway, increased activity o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ladd, Brendon, Mazzola, Anne Marie, Bihani, Teeru, Lai, Zhongwu, Bradford, James, Collins, Michael, Barry, Evan, Goeppert, Anne U., Weir, Hazel M., Hearne, Kelly, Renshaw, Jonathan G., Mohseni, Morvarid, Hurt, Elaine, Jalla, Sanjoo, Bao, Haifeng, Hollingsworth, Robert, Reimer, Corinne, Zinda, Michael, Fawell, Stephen, D'Cruz, Celina M.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342331/
https://ncbi.nlm.nih.gov/pubmed/27472462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10852
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados